Navigation Links
BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
Date:10/30/2009

ments that enable them to live longer, healthier, and fuller lives. Since 1923, Lilly has been an industry leader in pioneering therapies to help healthcare professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients. For more information about Lilly's current diabetes products, visit www.lillydiabetes.com.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

This press release contains forward-looking statements about Amylin and Lilly. Actual results could differ materially from those discussed or implied in this press release due to a number of risks and uncertainties, including the risk that BYETTA and the revenues generated from BYETTA may be affected by competition; unexpected new data; safety and technical issues; clinical trials not confirming previous results; pre-clinical trials not predicting future results; label expansion requests not being submitted in a timely manner or receiving regulatory approval; approved label expansions not producing the results we expect, or manufacturing and supply issues. The potential for BYETTA may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the commercialization of pharmaceutical products. These and additional risks and uncertainties are described more fully in Amylin's and Lilly's most recent SEC f
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
2. Surveyed Experts Indicate That Byetta LAR and Victoza Have Advantages Over Actos in the Treatment of Type 2 Diabetes
3. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
4. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
5. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
6. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
7. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
8. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
9. Clexane(R)/Lovenox(R) Approved in Japan
10. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
11. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... The next implants made from the ... mark (European) approval. The CE mark is necessary for ... and the European Union. Following the Class IIb approval ... implants supplied by the Turkey-based company Osimplant for the ... Cervical Expandable Bladed HA PEEK Cage line of spinal ...
(Date:3/4/2015)... 4, 2015 In an article published and ... for Health Security review the clinical aspects of diseases ... as bioweapons. The article, "Clinical Management of Potential Bioterrorism-Related ... website of the New England Journal of Medicine ... Toner , and Tom Inglesby—review the clinical management of ...
(Date:3/4/2015)... BARBARA, CALIFORNIA (PRWEB) March 04, 2015 ... consulting firm in the life sciences industry, hired ... Blewitt leads the Cloud Compliance Services and Solutions ... companies utilize cloud based applications while maintaining compliance with ... years, Blewitt has been an accomplished life sciences regulatory ...
(Date:3/4/2015)... CALGARY , March 4, 2015 /CNW/ ... that it has completed a collaborative research ... quantitative analytics.  Using Fast Collective Evolution Technology ... dataset including all measurements obtained from each ... Company,s Phase 2 clinical trials ASSERT, SUSTAIN ...
Breaking Biology Technology:Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3Latest Clinical Information On Bioterrorism Threats 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4
... Mass., April 17, 2012  ETEX Corporation, an advanced ... upcoming Global Technology Community 8th Stem Cell Summit, ... in Boston, MA. ETEX will highlight their cell ... Cell Commercialization & Partnering as well as Stem ...
... Inspiration Biopharmaceuticals, Inc. today announced that it has ... Food and Drug Administration (FDA) for the approval of ... the treatment and prevention of bleeding in individuals with ... of its agreement with Ipsen (Euronext: IPN; ADR: IPSEY), ...
... at the University of Wisconsin-Milwaukee (UWM) have discovered ... from the "wonder kid" of the carbon family, ... "graphene monoxide (GMO)," pushes carbon materials closer to ... layer of carbon that resembles a flat sheet ...
Cached Biology Technology:ETEX Corporation to Present at GTC Stem Cell Summit 2Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B 2Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B 3Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B 4UWM discovery advances graphene-based electronics 2UWM discovery advances graphene-based electronics 3
(Date:2/13/2015)... , Feb. 13, 2015 ACT Genomics ... that aims to transform cancer genomic information into ... the company has raised US$ 8 million in the ... in Taipei, Taiwan , ACT ... ACTOnco™. With the aim to implement next generation ...
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33
... linked to deafness in humans, researchers now have new insight ... ear send messages to the brain. The team reports its ... Cell, published by Cell Press. , The researchers found that ... deafness results from an inability to translate sound stimulation into ...
... and mammal hosts, Pacific Northwest National Laboratory scientists ... in the plague-bacterium Yersinia pestis whose numbers rise ... The team, led by the Department of Energy ... identified the proteins as “unique biomarkers related specifically ...
... of age are overweight or obese. However, less than one ... these health issues. This is one of the conclusions shown ... Medicine, and the University Hospital, published in the American ... [Spanish Journal of Cardiology] and Medicina Clínica ...
Cached Biology News:Critical hearing gene helps send auditory messages to brain 2Critical hearing gene helps send auditory messages to brain 3Plague proteome reveals proteins linked to infection 276 percent of workers older than 60 years of age are overweight or obese 2
... Description: ,Kit containing Dermal Fibroblasts (Mouse/BalbC) ... as a long-term culture, and is guaranteed ... continuous growth from the date supplied, when ... Dermis, mouse/BalbC, embryonic day 18.5 ,Applications: ...
... Protein A and Protein G bind ... immunoglobulins. Protein A and Protein G conjugates ... purify immunoglobulins (antibodies) and immunoglobulin subtypes from ... and other biological fluids. These reagents are ...
... a user-friendly statistical software package for scientists ... statistical analysis without being a statistical expert.Just ... and research and SigmaStat suggests the appropriate ... tests underlying assumptions and suggests another test ...
... We deliversoluble protein or No Charge to ... best soluble protein results , 24 solubility ... , Powerful results on your most insoluble ... Service (SOS) uses proprietary tools and know-how ...
Biology Products: